Adicet Bio Inc
ACET · NASDAQ
Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of 'off-the-shelf' gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.
Market Data
Price
$9.19
-0.19 (-2.03%)
Market Cap$78M
P/E Ratio—
EPS$—
52W High$17.44
52W Low$6.01
Beta1.63
Data from Finnhub · Updated Aug 24, 2026